Press Releases<< Back
Oncotype DX® Presentations at ASCO in Breast and Prostate Cancer Reinforce Genomic Health's Leadership in Optimizing Cancer Treatment
Two DCIS Studies Reinforce Independent Value of Oncotype DX DCIS Score™
A secondary analysis from the second large validation study conducted by the
A separate secondary analysis evaluated the correlation between the DCIS Score result and clinicopathologic features, such as age, tumor size, nuclear grade and multifocality. The results from 571 women with DCIS who had BCS alone and clear margins showed that the DCIS Score result quantifies risk of local recurrence independent of clinicopathologic features, reconfirming previous findings from the
"To accurately assess a patient's individual risk for cancer returning, we now have a tool like Oncotype DX that can provide important biological information beyond the traditional measures that had been available to physicians before," said
Baseline Characteristics from NCI-Sponsored Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, Confirmed Consistency of Oncotype DX Recurrence Score® Results Across Race and Ethnicity
An analysis of the study population enrolled in the TAILORx trial examined baseline patient characteristics, including race, ethnicity and body mass index (BMI), as well as their Recurrence Score results. The results showed no significant difference in Recurrence Score result distribution among Caucasian, African-American, Hispanic or Asian patients despite the clinical differences between those groups of patients. These data are consistent with prior studies that have shown that the Recurrence Score result provides information beyond that provided by clinical and pathologic features.
Coordinated by the
Study of Oncotype DX Genomic Prostate Score Underscores Value of Analyzing Gene Groups in Prostate Cancer
In prostate cancer, a study of 3,500 patient tumor samples processed in
"These scientific presentations reinforce the Company's successful approach to understanding risk assessment and, more importantly, emphasize our commitment to enabling physicians to individualize treatment plans for their patients," said
About Oncotype DX®
The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The Oncotype DX prostate cancer test identifies which clinically low risk patients are eligible for active surveillance, as well as those who may benefit from immediate treatment by predicting disease aggressiveness. With half a million patients tested in more than 80 countries, the Oncotype DX testing has redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about the Oncotype DX prostate cancer test, visit: www.OncotypeDX.com or www.myprostatecancertreatment.org.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the benefits of the test to physicians, patients and payors. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the ability of test results to change treatment decisions; the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; the risk that the company may not obtain or maintain sufficient levels of reimbursement, domestically or abroad, for its existing tests and any future tests it may develop; the risks of competition; unanticipated costs or delays in research and development efforts; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's quarterly report on Form 10-Q for the year ended March 31, 2015. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncotype-dx-presentations-at-asco-in-breast-and-prostate-cancer-reinforce-genomic-healths-leadership-in-optimizing-cancer-treatment-300090935.html
News Provided by Acquire Media